Literature DB >> 8921953

Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects.

C Barrios1, C Brandt, M Berney, P H Lambert, C A Siegrist.   

Abstract

We have recently shown that neonatal responses to a pannel of vaccine antigens and presentation systems differed qualitatively from adult responses by a bias towards a TH2 pattern. Here we report that a selected adjuvant comprising block copolymers in a water-in-oil emulsion can induce balanced TH1/TH2 responses in BALB/c mice primed at 1 week of age with an immunodominant tetanus peptide vaccine. However, using this specific TH1-driving adjuvant only at time of boosting was not sufficient to fully circumvent the persisting influence of TH2-biased neonatal responses. Unexpectedly also, a significant local toxicity was observed in newborn and young mice, whereas only mild reactions occurred in adults. Thus, although the induction of strong TH1 responses in the neonatal period can be achieved using specific adjuvants, through modulation of the immunological environment present at time of priming, whether such immunization strategies would be safe in the neonatal period remains to be demonstrated. These observations should be taken into consideration in the development of novel vaccines that will have to be already effective early in life.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8921953     DOI: 10.1002/eji.1830261118

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  26 in total

Review 1.  Immune mechanisms of childhood asthma.

Authors:  C E Donovan; P W Finn
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Type 1 and type 2 immune responses in children: their relevance in juvenile arthritis.

Authors:  L R Wedderburn; P Woo
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract.

Authors:  L M Bowman; P G Holt
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  Development of interleukin-12-producing capacity throughout childhood.

Authors:  John W Upham; Peter T Lee; Barbara J Holt; Tricia Heaton; Susan L Prescott; Mary J Sharp; Peter D Sly; Patrick G Holt
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.

Authors:  C L Brazolot Millan; R Weeratna; A M Krieg; C A Siegrist; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 6.  Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

Authors:  Patrick J Hanley; Conrad Russell Cruz; Elizabeth J Shpall; Catherine M Bollard
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

7.  DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life.

Authors:  X Martinez; C Brandt; F Saddallah; C Tougne; C Barrios; F Wild; G Dougan; P H Lambert; C A Siegrist
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

8.  Interferon-gamma, interleukin-4 and interleukin-10 production by T helper cells reveals intact Th1 and regulatory TR1 cell activation and a delay of the Th2 cell response in equine neonates and foals.

Authors:  Bettina Wagner; Alexandra Burton; Dorothy Ainsworth
Journal:  Vet Res       Date:  2010-04-09       Impact factor: 3.683

9.  B cells are dispensable for neonatal transplant tolerance induction.

Authors:  Wendy E Walker; Daniel R Goldstein
Journal:  Transplantation       Date:  2009-10-15       Impact factor: 4.939

10.  Murine neonates develop vigorous in vivo cytotoxic and Th1/Th2 responses upon exposure to low doses of NIMA-like alloantigens.

Authors:  Shannon J Opiela; Robert B Levy; Becky Adkins
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.